Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The K99 pilus antigen, also known as F5 fimbriae, is a filamentous surface protein found on certain strains of enterotoxigenic Escherichia coli (ETEC). It serves as a critical virulence factor by mediating the attachment of the bacteria to specific carbohydrate receptors, specifically N-glycolylneuraminic acid (Neu5Gc-GM3), on the intestinal epithelial cells of neonatal calves, lambs, and piglets [3, 7]. This adhesion is a prerequisite for colonization and the subsequent release of enterotoxins that cause severe, often fatal, diarrhea known as colibacillosis [2, 12]. Because of its essential role in pathogenesis, the K99 antigen is a primary target for veterinary vaccines and passive immunization strategies [9, 10]. Therapeutic interventions typically involve the administration of K99-specific monoclonal or polyclonal antibodies to neonates or the vaccination of pregnant dams to provide high levels of protective antibodies in the colostrum [6, 12]. By blocking the K99-mediated attachment, these treatments effectively prevent the establishment of infection in the gut [3, 6].
Neutralization of the K99 pilus antigen by specific antibodies prevents the attachment of enterotoxigenic Escherichia coli (ETEC) to the N-glycolylneuraminic acid (Neu5Gc) receptors on the intestinal brush border of neonatal animals. This blockade inhibits bacterial colonization and the subsequent production of enterotoxins, thereby preventing the development of severe diarrhea (colibacillosis).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on K99 pilus antigen (K99) (K99).